IP Library Granted Patent US 8,703,709
Granted Patent B2
US 8,703,709 · App. 13/491,408 · Granted Apr 22, 2014

Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,709
App. No.
13/491,408
Granted
Apr 22, 2014
Kind
B2
Abstract

Methods, compositions and articles of manufacture for contributing to the treatment of a solid cancerous tumor are disclosed. The methods, compositions and articles of manufacture can utilize an endothelin B agonist (ET B ) to enhance the delivery of a chemotherapeutic agent to a solid tumor in mammals, including humans.

Claims (13)

1. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620, (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for the administration of (a) and (b) for the treatment of a breast tumor in a mammal; and (d) a container for (a), (b), and (c).

2. The article of manufacture according to claim 1 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.

3. The article of manufacture according to claim 2 , wherein said chemotherapeutic agent is paclitaxel.

4. The article of manufacture according to claim 2 , wherein said chemotherapeutic agent is docetaxel.

5. The article of manufacture according to claim 2 , wherein said chemotherapeutic agent is daunorubicin.

6. The article of manufacture according to claim 1 , wherein when said instructions are followed, said IRL-1620 selectively increases blood supply to said breast tumor thus increasing the delivery of said chemotherapeutic agent to said breast tumor.

7. The article of manufacture according to claim 1 , wherein the pharmacokinetics of said chemotherapeutic agent are not affected by said IRL-1620.

8. The article of manufacture according to claim 1 , wherein said IRL-1620 enhances the efficacy of said chemotherapeutic agent.

9. An article of manufacture comprising: (a) a packaged composition comprising an IRL-1620; (b) a packaged composition comprising a chemotherapeutic agent; (c) an insert providing instructions for a simultaneous or sequential administration of (a) and (b) to treat a breast tumor in a mammal; and (d) a container for (a), (b), and (c).

10. The article of manufacture according to claim 9 , wherein said chemotherapeutic agent is selected from the group consisting of adriamycin, camptothecin, carboplatin, cisplatin, daunorubicin, doxorubicin, alpha interferon, beta interferon, gamma interferon, interleukin 2, irinotecan, docetaxel, paclitaxel, topotecan, and mixtures thereof.

11. The article of manufacture according to claim 10 , wherein said chemotherapeutic agent is paclitaxel.

12. The article of manufacture according to claim 10 , wherein said chemotherapeutic agent is docetaxel.

13. The article of manufacture according to claim 10 , wherein said chemotherapeutic agent is daunorubicin.

Assignments (3)
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT RECORDED AT REEL 061179/FRAME 0202 Recorded Aug 1, 2023
From: SLR INVESTMENT CORP.
To: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
Reel/Frame 064463/0709 →
SECURITY INTEREST Recorded Sep 22, 2022
From: SPECTRUM PHARMACEUTICALS, INC.; ALLOS THERAPEUTICS, INC.; TALON THERAPEUTICS, INC.
To: SLR INVESTMENT CORP., AS COLLATERAL AGENT
Reel/Frame 061179/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2012
From: GULATI, ANIL
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
Reel/Frame 028347/0431 →